Anton C M Martens
Overview
Explore the profile of Anton C M Martens including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
1551
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Deshantri A, Fens M, Ruiter R, Metselaar J, Storm G, Mandhane S, et al.
Hemasphere
. 2020 Sep;
4(5):e463.
PMID: 32923984
No abstract available.
2.
Deshantri A, Fens M, Ruiter R, Metselaar J, Storm G, van Bloois L, et al.
J Control Release
. 2019 Jan;
296:232-240.
PMID: 30682443
Glucocorticoids are the cornerstone in the clinic for treatment of hematological malignancies, including multiple myeloma. Nevertheless, poor pharmacokinetic properties of glucocorticoids require high and frequent dosing with the off-target adverse...
3.
Naik J, Themeli M, de Jong-Korlaar R, Ruiter R, Poddighe P, Yuan H, et al.
Haematologica
. 2018 Sep;
104(3):e100-e103.
PMID: 30190344
No abstract available.
4.
Drent E, Themeli M, Poels R, de Jong-Korlaar R, Yuan H, de Bruijn J, et al.
Mol Ther
. 2017 May;
25(8):1946-1958.
PMID: 28506593
Chimeric antigen receptors (CARs) can effectively redirect cytotoxic T cells toward highly expressed surface antigens on tumor cells. The low expression of several tumor-associated antigens (TAAs) on normal tissues, however,...
5.
Antonelli A, Noort W, Jaques J, de Boer B, de Jong-Korlaar R, Brouwers-Vos A, et al.
Blood
. 2016 Oct;
128(25):2949-2959.
PMID: 27733356
To begin to understand the mechanisms that regulate self-renewal, differentiation, and transformation of human hematopoietic stem cells or to evaluate the efficacy of novel treatment modalities, stem cells need to...
6.
de Haart S, Holthof L, Noort W, Minnema M, Emmelot M, Aarts-Riemens T, et al.
Haematologica
. 2016 May;
101(8):e339-42.
PMID: 27151995
No abstract available.
7.
Drent E, Groen R, Noort W, Themeli M, Lammerts van Bueren J, Parren P, et al.
Haematologica
. 2016 Feb;
101(5):616-25.
PMID: 26858358
Adoptive transfer of chimeric antigen receptor-transduced T cells is a promising strategy for cancer immunotherapy. The CD38 molecule, with its high expression on multiple myeloma cells, appears a suitable target...
8.
Van den Boom V, Maat H, Geugien M, Lopez A, Sotoca A, Jaques J, et al.
Cell Rep
. 2016 Jan;
14(2):332-46.
PMID: 26748712
Polycomb proteins are classical regulators of stem cell self-renewal and cell lineage commitment and are frequently deregulated in cancer. Here, we find that the non-canonical PRC1.1 complex, as identified by...
9.
Sarkar S, van Gelder M, Noort W, Xu Y, Rouschop K, Groen R, et al.
Cancer Immunol Immunother
. 2015 Apr;
64(8):951-63.
PMID: 25920521
Immunotherapy with allogeneic natural killer (NK) cells offers therapeutic perspectives for multiple myeloma patients. Here, we aimed to refine NK cell therapy by evaluation of the relevance of HLA-class I...
10.
Overdijk M, Verploegen S, Bogels M, van Egmond M, Lammerts van Bueren J, Mutis T, et al.
MAbs
. 2015 Mar;
7(2):311-21.
PMID: 25760767
Daratumumab (DARA) is a human CD38-specific IgG1 antibody that is in clinical development for the treatment of multiple myeloma (MM). The potential for IgG1 antibodies to induce macrophage-mediated phagocytosis, in...